Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 0.57 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.50 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | FDPS | P14324 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | LAP3 | P28838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL1049935 | 0.87 | SLC22A1 (0.67) | SLC22A1LPAR3SLC22A2LPAR2HSD17B10 | |
| Tetrabuthylammonium SCHEMBL9440008 | 0.87 | SLC22A1 (0.67) | SLC22A1LPAR3SLC22A2LPAR2HSD17B10 | |
| Tetrabuthylammonium SCHEMBL610139 | 0.87 | SLC22A1 (0.67) | SLC22A1LPAR3SLC22A2LPAR2HSD17B10 | |
| Tetrabuthylammonium SCHEMBL19834901 | 0.87 | SLC22A1 (0.67) | SLC22A1LPAR3SLC22A2LPAR2HSD17B10 | |
| Tetrabuthylammonium SCHEMBL28374654 | 0.85 | SLC22A1 (0.63) | SLC22A1LPAR3SLC22A2LPAR2HSD17B10 | |
| Tetrabuthylammonium SCHEMBL28547697 | 0.85 | SLC22A1 (0.63) | SLC22A1LPAR3SLC22A2LPAR2HSD17B10 | |
| Tetrabuthylammonium SCHEMBL28346602 | 0.85 | SLC22A1 (0.63) | SLC22A1LPAR3SLC22A2LPAR2HSD17B10 | |
| Tetrabuthylammonium SCHEMBL29164921 | 0.85 | SLC22A1 (0.63) | SLC22A1LPAR3SLC22A2LPAR2HSD17B10 | |
| Tetrabuthylammonium SCHEMBL28973536 | 0.85 | SLC22A1 (0.63) | SLC22A1LPAR3SLC22A2LPAR2HSD17B10 | |
| Tetrabuthylammonium SCHEMBL28261378 | 0.85 | SLC22A1 (0.63) | SLC22A1LPAR3SLC22A2LPAR2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109206464-B | Adenosine diphosphate ribose compound and preparation method and biological activity thereof | 北京大学 | 2020-12-11 | — | — | CN | disclosed |
| US-20140100198-A1 | ENZYME INHIBITING COMPOUNDS AND METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-04-10 | — | — | US | disclosed |
| US-8609638-B2 | Enzyme inhibiting compounds and methods | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-12-17 | — | — | US | disclosed |
| US-20120196835-A1 | ENZYME INHIBITING COMPOUNDS AND METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-08-02 | — | — | US | disclosed |
| WO-2011044505-A2 | ENZYME INHIBITING COMPOUNDS AND METHODS | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20070225246-A1 | O-acetyl-ADP-ribose non-hydrolyzable analogs | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-27 | — | — | US | disclosed |
| EP-1165573-B1 | COMPOUNDS SELECTIVELY INHIBITING GAMMA 9 DELTA 2 T LYMPHOCYTES | INST NAT SANTE ETDE LA RECH ME (FR) | 2004-01-21 | — | — | EP | disclosed |
| US-20040009123-A1 | Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2004-01-15 | — | — | US | disclosed |
| US-20040006131-A1 | Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2004-01-08 | — | — | US | disclosed |
| US-6624151-B1 | Concerns the uses of said compounds as selective inhibitors of T gamma 9 delta 2 lymphocytes, their uses, for therapeutic purposes. | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2003-09-23 | — | — | US | disclosed |
| EP-1165573-A1 | COMPOUNDS SELECTIVELY INHIBITING GAMMA 9 DELTA 2 T LYMPHOCYTES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059916-A1 | COMPOUNDS SELECTIVELY INHIBITING GAMMA 9 DELTA 2 T LYMPHOCYTES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006131-A1 | Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes | CD4, IL2RA, CD74 | SLC22A1 3427/4885LPAR3 974/4885SLC22A2 3112/4885 |
| US-20120196835-A1 | ENZYME INHIBITING COMPOUNDS AND METHODS | COASY, FADS2, FDPS | SLC22A1 3366/4885LPAR3 3076/4885SLC22A2 3642/4885 |
| US-20070225246-A1 | O-acetyl-ADP-ribose non-hydrolyzable analogs | PARP1, TIPARP, CD38 | SLC22A1 4146/4885LPAR3 721/4885SLC22A2 4232/4885 |
| US-20140100198-A1 | ENZYME INHIBITING COMPOUNDS AND METHODS | COASY, FADS2, FDPS | SLC22A1 3366/4885LPAR3 3076/4885SLC22A2 3642/4885 |
| US-20040009123-A1 | Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes | CD4, IL2RA, CD74 | SLC22A1 3427/4885LPAR3 974/4885SLC22A2 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.